WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Hypertensive Disorders of Pregnancy: Exploring Epidemiology, Risk Factors, Maternal-Fetal Outcomes, and Comprehensive Management and Prevention Strategies – A Review

Priyanka Malaiyappan[1*], Augusta Rebecca James Ravichandran[2]

[1]Medical Officer, Manam Healthcare Hospital, Tamil Nadu, India
[2]Medical Practitioner, Abraham's Healthcare Center, Tamil Nadu, India
Email: drpriyamalaiy@gmail.com
DOI : https://doi.org/10.55248/gengpi.6.0425.14187

ABSTRACT

Hypertensive Disorders of Pregnancy (HDPs), including gestational hypertension, preeclampsia, and chronic hypertension, are among the most significant contributors to maternal and neonatal morbidity and mortality, worldwide. These disorders affect approximately 5–10% of pregnancies globally, with variations driven by socioeconomic and healthcare disparities, particularly pronounced in low-resource settings such as rural India. Hypertensive disorders of pregnancy are associated with adverse outcomes, including placental abruption, intrauterine growth restriction, preterm birth, and long-term maternal cardiovascular and renal complications. Recent research highlighted the roles of genetic predispositions, epigenetic modifications, and gut microbiota in HDP pathophysiology, offering novel insights into prevention and management. Advances in pharmacological treatment, telemedicine integration, and personalized care strategies are improving outcomes, though gaps in global clinical guidelines and healthcare access persist. This review synthesizes the current evidence on the epidemiology, risk factors, maternal and fetal complications, and management strategies for hypertensive disorders of pregnancy, emphasizing innovative approaches to reduce their burden and promote equitable maternal and neonatal health outcomes.

Keywords: Hypertensive Disorders of Pregnancy, Gestational Hypertension, Pregnancy-induced hypertension, Preeclampsia, Maternal Outcomes, Fetal Outcomes

1. Introduction

Hypertension during pregnancy, encompassing a spectrum of hypertensive disorders, such as chronic hypertension, gestational hypertension, preeclampsia, and eclampsia, represents one of the leading contributors to maternal and perinatal morbidity and mortality globally. These hypertensive disorders collectively affect approximately 10% of pregnancies worldwide, with variations noted across regions due to socio-economic and healthcare disparities. For instance, prevalence rates of gestational hypertension and preeclampsia range from 6–8% and 2–4%, respectively, while chronic hypertension accounts for 1–3%.[1] India faces a significant burden of hypertensive disorders of pregnancy, with national estimates suggesting prevalence rates of approximately 11%. Key determinants include limited prenatal screening, low socioeconomic status, and inadequate access to healthcare resources, particularly in rural and underserved populations.[2] Regional studies, such as those conducted in Bengaluru, report higher prevalence rates of HDPs at 13.9% among pregnant women in public sector hospitals, driven by factors such as obesity, maternal age, nulliparity, and prenatal anxiety.[3] These alarming statistics emphasize the urgent need for targeted interventions to mitigate their impact. Gestational hypertension and preeclampsia are the most common types of hypertensive disorder in pregnancy and these conditions are associated with adverse maternal and fetal outcomes.[4] HDPs are associated with adverse outcomes, including placental abruption, intrauterine growth restriction, neonatal morbidity, and maternal cardiovascular disease. Severe forms such as preeclampsia and HELLP syndrome further compound these risks, leading to complications such as disseminated intravascular coagulation, acute renal failure, and postpartum haemorrhage.[5, 6] Moreover, a history of HDP significantly elevates long-term health risks, such as chronic kidney disease, coronary artery disease, and stroke, underscoring the importance of early diagnosis and comprehensive management strategies.[7, 8] Recent advances in research have identified genetic and molecular factors contributing to HDP pathophysiology, including single-nucleotide polymorphisms in the angiotensinogen gene and disruptions in angiogenic signalling pathways involving placental growth factor and soluble fms-like tyrosine kinase-1.[7, 9] These findings have paved the way for novel diagnostic and therapeutic approaches, such as predictive biomarker assays and targeted pharmacological interventions, which promise to improve HDP management and outcomes. However, the lack of uniformity in global clinical guidelines, particularly regarding aspirin prophylaxis and blood pressure thresholds for initiating treatment, presents a challenge to standardizing care.[10] This review synthesizes findings from research papers to provide a comprehensive analysis of HDPs, focusing on their epidemiology, risk factors, complications, management strategies, and long-term implications. By addressing these aspects, the review aims to enhance understanding and inform evidence-based policies and practices for improving maternal and neonatal health outcomes. Furthermore, the review highlights the importance of

integrating advanced technologies, such as telemedicine and remote blood pressure monitoring, into maternal healthcare systems to bridge gaps in care delivery, particularly in underserved regions.[11] Through this analysis, the review seeks to contribute to global efforts in reducing the burden of HDPs and achieving equitable maternal and fetal health care.

1.1 Epidemiology Of Hypertensive Disorders in Pregnancy

Hypertensive disorders of pregnancy (HDPs) affect approximately 5–10% of pregnancies globally, making them one of the most prevalent complications in obstetric care. A population-based study conducted in sub-Saharan Africa and South Asia revealed a 10% incidence of hypertension in pregnancy, highlighting significant variations across countries, even after accounting for measurable baseline maternal characteristics. Among the HDP subtypes, gestational hypertension was the most common, accounting for 6–8% of pregnancies, followed by preeclampsia at 2–4%, and chronic hypertension at 1–3%.[1, 12] India, with its socio-cultural diversity, faces a unique set of challenges in combating HDPs. Regional studies, such as those conducted in Bengaluru, underscore a prevalence rate of 13.9% among pregnant women attending public healthcare facilities. The higher incidence in urban centers like Bengaluru is attributed to modifiable risk factors such as obesity, employment stress, and lifestyle behaviors, alongside non-modifiable determinants like advanced maternal age and nulliparity.[2, 3] The nationwide prevalence of HDPs is estimated at 11%, with significant disparities observed between rural and urban settings due to variations in access to prenatal care and health education.[2, 12] Haemorrhage, sepsis and hypertensive disorders are also significant contributors to maternal and neonatal mortality. Among the hypertensive conditions, preeclampsia and eclampsia exert the most profound impact, accounting for a substantial proportion of maternal deaths in low-resource settings.[5] In addition to immediate obstetric complications, women diagnosed with HDPs during pregnancy are at an elevated risk of chronic diseases, including hypertension, cardiovascular disorders, and renal dysfunction, further emphasizing their public health importance.[8, 13] Understanding the epidemiological landscape of HDPs is crucial for designing targeted preventive strategies. Regional disparities necessitate tailored interventions to address modifiable risk factors while also improving healthcare delivery for marginalized populations. Through robust surveillance systems and community-level education, early detection and timely management of HDPs can be significantly enhanced.

1.2 Risk Factors and Determinants of Hypertensive Disorders in Pregnancy

Hypertensive disorders in pregnancy (HDPs) are influenced by a complex interplay of modifiable and non-modifiable risk factors, which have been extensively documented across diverse populations. Modifiable risk factors, such as body mass index (BMI), anemia, and lower education levels, have been strongly associated with an increased likelihood of HDPs. [3, 7] Lifestyle-related determinants, including obesity and employment-related stress, further exacerbate the prevalence of these disorders, particularly in urbanized settings.[3] Non-modifiable risk factors for HDPs include maternal age, nulliparity, and genetic predispositions. A single nucleotide polymorphism in the angiotensinogen gene has been identified as a genetic determinant of susceptibility to HDPs.[7] Family history of hypertension and prior occurrences of chronic hypertension or preeclampsia significantly elevate the risk of developing HDPs during subsequent pregnancies.[14] Among obstetric risk factors, multigravidity, multiple pregnancies, and a gestational age exceeding 20 weeks have emerged as independent predictors for hypertension during pregnancy.[12] Furthermore, certain socioecological determinants unique to low-resource settings, particularly rural areas in India, contribute to heightened HDP prevalence. Limited prenatal screening, inadequate health literacy, and socio-economic disparities emerge as critical factors influencing HDP occurrence.[2] Addressing these risk factors holistically involves leveraging evidence-based interventions, such as targeted education programs, lifestyle modifications, and regular antenatal screenings, to mitigate the prevalence and severity of hypertensive disorders during pregnancy. For primary care physicians, profiling risk factors early in pregnancy remains vital for preventing adverse maternal and fetal outcomes.[3] The interplay of modifiable and non-modifiable risk factors presents a unique opportunity for preventive strategies, underscoring the need for continued research to identify determinants and address disparities in care delivery, thereby inspiring future exploration into mitigating the burden of HDPs worldwide.

1.3 Epigenetics and Gut Microbiota of Hypertensive Disorder of Pregnancy

Recent studies have identified a significant link between gut microbiota composition and hypertensive disorders of pregnancy (HDP). Specific microbial genera were associated with various HDP subtypes: LachnospiraceaeUCG010 and Bifidobacterium with gestational hypertension, Tyzzerella3 with preeclampsia, and Dorea with eclampsia.[15] These findings emphasize the role of gut microbiota in HDP pathophysiology and open pathways for microbiome-targeted interventions. Additionally, pregnant women with HDP exhibit lower dietary intake of vitamins A and C, contributing to altered microbiota profiles. A negative correlation between Bifidobacterium abundance and HDP risk highlights the potential benefits of nutrition-driven strategies, such as probiotics and vitamin C supplementation, in HDP prevention and management.[16] By tailoring interventions such as probiotics, prebiotics, and specific micronutrient supplementation, maternal health outcomes can be improved. Future studies should explore the longitudinal impact of microbiota-based therapies and their capacity to complement existing treatments for HDPs. Integrating dietary and microbiome-targeted interventions into antenatal care programs could provide a cost-effective and sustainable approach to reducing the burden of HDPs while enhancing maternal and neonatal health outcomes. Epigenetic alterations play a pivotal role in pregnancy-induced hypertension (PIH), impacting placental function and maternal-fetal health. DNA methylation changes affect placental trophoblast function, nutrient transport, and perfusion, contributing to PIH pathophysiology. Methylation profiles in maternal and umbilical cord blood show potential as biomarkers for early diagnosis and prevention of PIH. Beyond maternal health, these epigenetic modifications have transgenerational effects, predisposing offspring to chronic conditions like cardiovascular disease and diabetes.[17] Studies have also identified HDP-associated CpG site methylation changes, linked to developmental and neurological pathways, with

persistent signatures observed from birth to adolescence.[18] These findings underscore the need for further research into therapeutic strategies targeting epigenetic regulation to mitigate the risks associated with PIH.

2. Complications and Adverse Outcomes of Hypertensive Disorders in Pregnancy

Hypertensive disorders in pregnancy (HDPs), such as chronic hypertension, gestational hypertension, preeclampsia, and eclampsia, significantly contribute to adverse maternal and fetal outcomes, making them one of the most critical challenges in obstetric care globally.[19] These conditions are associated with an array of complications requiring timely clinical interventions to mitigate risks to maternal and neonatal health.

2.1 Maternal Complications

HDPs elevate the risk of severe obstetric conditions such as placental abruption, postpartum hemorrhage, disseminated intravascular coagulation.[20] and acute renal failure. Placental abruption, affecting 14.1% of pregnancies with pregnancy-induced hypertension (PIH), presents with alarming symptoms, including abdominal tenderness, vaginal bleeding, and elevated maternal blood pressures, which contribute to maternal and fetal morbidity and mortality.[21] Additionally, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), a variant of preeclampsia, is linked to severe hepatic dysfunction and acute renal failure, particularly in cases with prior occurrences in early pregnancies.[22, 23] Eclampsia, characterized by seizures, neurologic impairments, and vascular compromise, remains a leading cause of maternal mortality in developing countries, despite advancements in antenatal care.[22] Studies also highlight a notable association between maternal HDPs and an increased risk of cesarean delivery, cardiomyopathy, and cardiovascular diseases within postpartum years, reinforcing the need for long-term health monitoring.[8, 24] Maternal deaths linked to hypertensive disorders often arise from complications such as adherent placenta, severe hypertension, and preeclampsia-related comorbidities, illustrating their critical impact on maternal health.[24, 25] Pregnancies complicated by placenta previa exhibit significantly higher rates of hypertensive disorders, intrauterine growth restriction, placental abruption, and perinatal mortality. Placenta previa plays a critical role in altering placental function, which contributes to these adverse outcomes.[26] Women diagnosed with pregnancy-induced hypertension exhibited a significant prevalence of ocular manifestations. Among hypertensive disorders, severe pre-eclampsia was associated with the highest incidence of retinal changes, indicating potential vascular compromise. Identified proteinuria as a significant correlate of retinal alterations, suggesting its role in the severity of hypertensive retinopathy.[27] Blood investigations revealed significant thrombocytopenia in cases of eclampsia, reflecting severe disease progression. Additionally, decreased prothrombin time was observed in cases of gestational hypertension, indicating potential alterations in coagulation pathways.[28] The complications arising from hypertensive disorders of pregnancy highlight their profound impact on maternal and fetal health. From placental abruption to long-term cardiovascular risks, HDPs necessitate effective management and ongoing monitoring. Identifying biomarkers and refining preventive strategies can mitigate progression and improve outcomes, paving the way for enhanced maternal care.

2.2 Fetal and Neonatal Complications

Fetal complications linked to HDPs include intrauterine growth restriction (IUGR), preterm births, neonatal asphyxia, and low birth weight.[20, 29, 30] Compromised placental perfusion resulting from gestational hypertension and preeclampsia limits fetal oxygenation, leading to severe outcomes like respiratory distress syndrome (RDS), particularly among very low birth weight (VLBW) neonates.[31, 32] Chronic hypertension in pregnancy is significantly associated with placenta-mediated complications, including fetal growth restriction, preterm delivery, perinatal mortality, and an elevated risk of developing superimposed preeclampsia.[33] For neonates born before 30 weeks of gestation to mothers diagnosed with PIH, there is a significantly elevated risk of bronchopulmonary dysplasia, emphasizing the necessity for specialized neonatal care.[31] Examined the fetoplacental weight relationship in normal pregnancies as well as pregnancies complicated by PIH and placental abruption. Significant differences in placental weight and fetal weight were observed across these groups, with lower placental weights and diameters recorded in PIH and abruption cases. The mean fetoplacental ratio was also lowest in placental abruption cases, emphasizing the impaired placental function in these conditions.[34] Pregnancies complicated by HDPs also show higher rates of small-for-gestational-age (SGA) infants and neonatal mortality, with survival rates substantially lower among preterm neonates born to hypertensive mothers.[29, 35] These adverse outcomes necessitate advanced neonatal care interventions and targeted perinatal strategies to improve survival and reduce morbidities in affected new-borns.

2.3 Long-Term Implications

The impact of HDPs extends beyond the immediate pregnancy period, significantly affecting the long-term health of both mothers and offspring. Women with histories of HDPs are at elevated risks of chronic hypertension, coronary artery disease, renal dysfunction, and diabetes mellitus, highlighting the importance of postpartum health surveillance.[8, 9] Women with a history of pregnancy-induced hypertension (PIH) exhibit a significantly increased risk of developing atrial flutter, fibrillation, and atrioventricular block compared to those with normotensive pregnancies. Notably, while PIH contributes to a higher occurrence of arrhythmias, no increase in lethal arrhythmias.[36] Moreover, maternal HDPs are associated with increased all-cause mortality in offspring, particularly cardiovascular and metabolic disorders during their developmental years, necessitating closer health monitoring.[37] The implementation of early postural interventions in postpartum women with pregnancy-induced hypertension (PIH) demonstrates significant potential in mitigating the risk of long-term complications. By promoting venous return and preventing deep venous thrombosis (DVT), these interventions contribute to improved postpartum recovery and reduced likelihood of chronic vascular conditions.[38] The interplay between maternal hypertensive conditions and

adverse fetal outcomes underscores the need for integrated antenatal care, timely diagnoses, and evidence-based management strategies. By addressing these challenges, healthcare providers can mitigate the complications arising from HDPs and foster improved maternal and neonatal health outcomes.

3. Management and Preventive Strategies for Hypertensive Disorders of Pregnancy

Effective management and prevention of hypertensive disorders in pregnancy (HDPs) hinge on timely detection, comprehensive antenatal care, and evidence-based interventions tailored to individual risks. Clinical guidelines emphasize a holistic approach encompassing pharmacological treatments, lifestyle modifications, and advanced obstetric practices to mitigate adverse maternal and neonatal outcomes.[5, 6]

3.1 Medication Interventions

Antihypertensive medications remain the cornerstone of managing hypertensive disorders during pregnancy.[39] Labetalol, nifedipine, and hydralazine are the preferred first-line antihypertensive medications during pregnancy due to their efficacy and established safety profiles. Clonidine, methyldopa, and thiazide diuretics such as chlorthalidone and hydrochlorothiazide are classified as second- or third-line options. Hydrochlorothiazide, at doses of 50 mg or less, is considered safe for use during breastfeeding. Amlodipine, though categorized as probably safe, requires further research to confirm its complete safety profile.[40–43] Angiotensin-converting enzyme inhibitors such as benazepril, captopril, enalapril, and lisinopril, along with angiotensin receptor blockers like losartan, olmesartan, and valsartan, are contraindicated due to teratogenic risks. Atenolol and mineralocorticoid antagonists, including spironolactone, amiloride, and eplerenone, are also unsuitable during pregnancy.[40–44] Institutional practice to use oral antihypertensive medications for hypertensive disorders of pregnancy undergoing expectant management. However, most HDP cases occur at or near term, where delivery is the preferred management approach. The difference in antihypertensive medication uses between chronic hypertension and co-existing CHTN with HDP groups may reflect more severe disease in medication-requiring cases, or the expectant management of superimposed HDP.[40–42] Randomized trials comparing labetalol and nifedipine have demonstrated both drugs' efficacy, with nifedipine exhibiting a more pronounced reduction in arterial stiffness.[45] While antihypertensive treatments reduce severe hypertension occurrences, their impact on preventing superimposed preeclampsia remains inconclusive, necessitating further clinical research.[46] These pharmacological measures have proven instrumental in stabilizing maternal health and minimizing obstetric emergencies.

3.2 Preventive Strategies

Preventive measures focus on identifying and mitigating modifiable risk factors. Calcium supplementation, particularly in populations with insufficient dietary calcium intake, has demonstrated efficacy in reducing preeclampsia risks.[5] Early profiling of risk factors such as maternal age, prenatal anxiety, and obesity during antenatal visits allows for targeted lifestyle interventions and community education programs aimed at minimizing HDP prevalence.[2, 3] Additionally, aspirin prophylaxis initiated between early and mid-pregnancy has been recommended to reduce preeclampsia risks in high-risk women, with international guidelines advocating dosages ranging from 75 mg to 162 mg.[10] This preventive approach underscores the importance of personalized healthcare strategies in improving maternal outcomes. Advancements in remote monitoring technologies have revolutionized postpartum hypertension management, enabling real-time blood pressure surveillance and timely medication adjustments. Remote protocols integrated with telemedicine have proven effective in bridging gaps in postpartum care and enhancing compliance with clinical guidelines.[11] Such innovations hold significant promise for improving maternal health outcomes beyond delivery. Optimal timing of delivery is crucial for mitigating HDP-related risks. For women with chronic hypertension, planned early-term delivery between 38 and 40 weeks has been recommended to minimize complications while ensuring neonatal safety.[47] Individualized management strategies based on maternal-fetal status are critical in balancing interventionist and expectant approaches in severe preeclampsia cases before term. Comprehensive management of HDPs relies on strengthening prenatal care services, improving health literacy among pregnant women, and expanding community-level interventions for early detection. These strategies collectively contribute to better maternal and neonatal health outcomes, laying the foundation for long-term wellness. The international guidelines for the management of hypertensive disorders of pregnancy (HDPs) outline critical recommendations aimed at optimizing maternal and fetal outcomes. These guidelines, developed by organizations such as WHO, ACOG, and UK NICE, exhibit variations in key aspects, including screening protocols, antihypertensive thresholds, preferred medications, and aspirin prophylaxis. Screening protocols vary from universal BP monitoring with routine urine protein analysis to targeted risk-based approaches. Antihypertensive treatment thresholds differ as well, with some guidelines initiating treatment at blood pressure levels of 140/90 mmHg, while others recommend starting at 150/100 mmHg or higher. The choice of preferred antihypertensive agents also reflects regional practices, with medications such as methyldopa, labetalol, and nifedipine commonly recommended, while agents like ACE inhibitors and ARBs are universally contraindicated. Furthermore, variations in aspirin prophylaxis both in dosage and initiation timing underscore the emphasis on tailoring care to specific patient risk profiles. Additionally, fetal surveillance strategies, including Doppler ultrasound, biophysical profiles, and growth monitoring, are highlighted across guidelines to ensure maternal and neonatal safety [48–50], are summarized in Table 1. These insights underscore the necessity of adapting care approaches to align with regional healthcare contexts, resource availability, and population needs, ensuring equitable and evidence-based management of HDPs globally.

Table 1: Global Guidelines for Management of Hypertensive Disorders in Pregnancy

Aspect	WHO Guidelines [49]	ACOG Guidelines [48]	UK NICE Guidelines [50]
Screening Recommendations	Universal BP monitoring at each prenatal visit.	Universal BP monitoring with routine urine protein analysis.	BP monitoring and urine protein analysis; assess for risk factors.
Antihypertensive Threshold	Start treatment at BP ≥ 140/90 mmHg.	Initiate treatment at BP ≥ 160/110 mmHg.	Commence management at BP ≥ 150/100 mmHg.
Preferred Antihypertensives	Methyldopa, Labetalol, Nifedipine.	Labetalol, Nifedipine, Hydralazine.	Labetalol, Methyldopa, Nifedipine.
Management of Severe Preeclampsia	Magnesium sulphate for seizure prevention.	Magnesium sulphate recommended.	Magnesium sulphate in severe cases only.
Aspirin Prophylaxis	Recommended for high-risk women (75 mg).	Initiate 81 mg daily for women at risk of PE.	Recommend 75 mg daily for high-risk women.
Fetal Surveillance	Doppler ultrasound for growth assessment.	Ultrasound every 3–4 weeks	Regular growth scans and fetal monitoring in severe cases.

4. Long-Term Health Implications for Mothers and Offspring

Hypertensive disorders of pregnancy (HDPs) not only pose immediate risks but also have profound long-term consequences for both mothers and their offspring. Emerging evidence underscores the need for early recognition of HDPs as a predictor of chronic conditions, emphasizing the role of pregnancy as a physiological stress test that reveals underlying vulnerabilities in maternal health.[51]

4.1 Maternal Health Outcomes

Women with a history of HDPs face significantly elevated risks of developing chronic hypertension, cardiovascular diseases (CVDs), and renal dysfunction in later life.[8] Long-term studies have revealed that HDPs are associated with heightened arterial stiffness indices, coronary artery disease, and heart failure, with prior preeclampsia identified as a strong predictor of these conditions.[9, 52] Moreover, women with both HDPs and pre-pregnancy hypertension exhibit compounded risks, including mortality, within 1, 3 and 5 years postpartum .[53] Chronic kidney disease (CKD) is another critical long-term consequence of HDPs. Women who experienced HDP or pre-pregnancy hypertension faced significantly increased risks of kidney disease within three, five, and 14 years postpartum.[13] These findings highlight the need for continuous postpartum monitoring and interventions targeting renal and cardiovascular health to improve long-term outcomes. Beyond physiological impacts, HDPs contribute to postpartum functional disabilities, as measured by tools such as the WHO Disability Assessment Schedule 2.0.[54] Women affected by HDPs frequently report limitations in physical functioning and quality of life, underscoring the importance of comprehensive postpartum care.

4.2 Offspring Health Outcomes

The effects of HDPs extend to offspring, increasing their risk of adverse health outcomes that persist into adulthood. Maternal HDPs have been linked to a higher risk of all-cause mortality in offspring, driven by conditions such as cardiovascular and metabolic disorders, as well as perinatal complications.[37] Studies have also observed elevated rates of small-for-gestational-age (SGA) neonates and low birth weight among children born to hypertensive mothers, predisposing them to developmental delays and chronic conditions.[32, 35] Children exposed to HDPs in utero are at an increased risk of hypertension, obesity, and type 2 diabetes mellitus in adolescence and adulthood.[37, 51] These findings underscore the intergenerational impact of HDPs, highlighting the importance of preventive strategies aimed at improving maternal and child health.

4.3 Implications for Clinical Practice

Given the significant long-term health implications of HDPs, healthcare providers must adopt a life-course approach to care. This involves comprehensive postpartum follow-up for women with a history of HDPs, including regular cardiovascular and renal assessments.[13] Early interventions, such as lifestyle modifications and pharmacological treatments, can mitigate the risk of chronic conditions and improve overall health outcomes. Similarly, paediatric follow-up for children born to hypertensive mothers is essential to monitor growth trajectories and identify early markers of chronic diseases. Public health initiatives aimed at educating communities about the long-term risks associated with HDPs can also play a pivotal role in improving health outcomes for affected families.

5. Innovative Approaches and Research Directions in Hypertensive Disorders of Pregnancy

Hypertensive disorders of pregnancy (HDPs) continue to be a focus of robust research and innovative interventions aimed at improving maternal and neonatal outcomes. Emerging technologies, novel therapeutic strategies, and global collaborative efforts are reshaping how HDPs are detected, managed, and prevented. This section delves into cutting-edge research directions and innovations that are transforming the landscape of maternal healthcare.

5.1 Genetic Insights and Biomarker Discovery

Advances in genomics have unveiled significant genetic predispositions to HDPs, including single-nucleotide polymorphisms (SNPs) in genes such as angiotensinogen, which modulate maternal susceptibility to hypertensive disorders.[7] Genome-wide association studies (GWAS) have identified key loci contributing to gestational hypertension and preeclampsia, paving the way for personalized healthcare approaches. Predictive biomarkers, such as circulating placental growth factor (PLGF) and soluble fms-like tyrosine kinase-1, have shown promise in early detection of HDPs, allowing for timely interventions and monitoring of disease progression.[9] Integrating genetic and biomarker insights into clinical practice offers an opportunity to develop precision medicine approaches, enhancing risk stratification and tailoring preventive strategies to individual maternal profiles. These advancements highlight the transformative potential of genomics and biomarkers in improving maternal and neonatal outcomes for hypertensive disorders of pregnancy.

5.2 Remote Monitoring and Telemedicine

Innovative remote monitoring protocols are revolutionizing postpartum hypertension management, particularly in underserved communities. Telemedicine platforms integrated with wearable devices enable real-time surveillance of maternal blood pressure and facilitate early clinical decision-making, reducing risks associated with delayed care.[11] These approaches not only enhance compliance with clinical guidelines but also bridge healthcare gaps in resource-limited settings, emphasizing scalability for broader implementation.

5.3 Pharmacological Innovations

The landscape of antihypertensive treatment for HDPs is evolving, with randomized controlled trials highlighting the differential benefits of drugs such as labetalol and nifedipine. Comparative studies demonstrate nifedipine's superior ability to reduce arterial stiffness, although further exploration is needed to assess long-term impacts.[45] Meanwhile, targeted therapies like magnesium sulphate remain the gold standard for managing eclampsia, and corticosteroids have demonstrated effectiveness in HELLP syndrome cases, optimizing maternal health outcomes.[40] The importance of tailoring therapeutic strategies to optimize outcomes for hypertensive disorders of pregnancy. Continued research into drug efficacy and long-term impacts will further refine management approaches, enhancing maternal and neonatal care.

5.4 Predictive Models and Risk Stratification

The development of predictive models integrating individual and systemic risk factors for HDPs has enhanced precision medicine in obstetric care. Logistic regression-based frameworks incorporating variables such as BMI, maternal age, albuminuria, severity of disease, uterine atony, HDL-C, LDL-C and vascular endothelial growth factor (VEGF) abnormalities provide accurate risk assessments for complications like postpartum hemorrhage and preterm labor.[55] These models hold potential for widespread clinical adoption to reduce HDP-related morbidities.

5.5 Implications for Global Collaborative Research

International guidelines for HDP prevention and management emphasize the importance of global collaboration in research and healthcare delivery. Comparative analyses of guidelines reveal differences in aspirin dosage for preeclampsia prevention, antihypertensive thresholds, and management strategies across countries, necessitating standardized approaches for improving maternal and fetal outcomes worldwide.[10] These efforts underscore the need for culturally relevant practices tailored to regional healthcare systems. Despite advancements, critical gaps remain in HDP research, including understanding delayed-onset postpartum preeclampsia and optimizing therapeutic strategies.[56] Future research must prioritize exploring molecular mechanisms underlying HDPs, evaluating innovative therapies, and addressing disparities in healthcare access. Expanding surveillance systems and fostering interdisciplinary collaboration will be essential for tackling HDPs comprehensively. Despite advancements in maternal healthcare, managing hypertensive disorders in pregnancy (HDPs) remains a global challenge, particularly in resource-limited settings. Disparities in healthcare delivery, social determinants of health, and systemic inequities contribute to elevated risks among vulnerable populations, emphasizing the need for innovative solutions and policy reforms.

5.6 Socioeconomic and Systemic Barriers

In developing regions such as rural India, systemic barriers including limited access to prenatal screening, inadequate health literacy, and minimal community-level education on HDPs contribute to poorer outcomes. Only 21% of pregnant women in India utilize prenatal care services, with socially disadvantaged groups accessing them far less.[2] This lack of healthcare engagement reduces opportunities for early risk factor identification and timely interventions, exacerbating maternal and neonatal complications. Financial constraints often prevent low-income families from availing adequate

antenatal care, while socioeconomic pressures can elevate stress levels among pregnant women, further contributing to HDP prevalence. Employment outside the home, identified as a significant risk factor in urban centers like Bengaluru, reflects broader occupational stress affecting maternal health outcomes.[3] Addressing these disparities requires systemic interventions aimed at improving healthcare accessibility, affordability, and quality. Healthcare systems in many low-resource countries face infrastructural deficits, including shortages of trained medical professionals, BP monitoring devices, and transport facilities such as ambulances. The third delay in maternal care the delay in receiving necessary interventions represents a significant barrier to reducing maternal mortality. Inadequate health financing mechanisms and delayed referrals exacerbate complications, particularly for HDPs requiring emergency care.[57] Improving prenatal screening, community education, affordable care, and healthcare infrastructure can reduce the burden of hypertensive disorders of pregnancy. Prioritizing timely referrals, emergency care, and stress management is essential for bridging disparities and ensuring equitable maternal outcomes.

5.7 Disparities in High-Income Countries

Even in high-income countries, racial and ethnic disparities persist in maternal healthcare access and outcomes. Non-Hispanic Black women experience disproportionately higher risks of HDP-related complications, including maternal mortality, chronic hypertension, and long-term cardiovascular disorders compared to White women.[53] These disparities highlight the intersection of socioeconomic, racial, and systemic factors in shaping maternal health outcomes, warranting targeted interventions. To address these challenges, healthcare providers and policymakers must prioritize community-level education, enhance culturally relevant practices, and strengthen referral systems for obstetric care. The integration of remote monitoring technologies, such as telemedicine platforms, offers scalable solutions for improving postpartum hypertension management and reducing HDP-related risks across diverse populations.[11] Meanwhile, efforts to standardize international guidelines for HDP management can foster equitable care delivery across different regions, aligning practices with evidence-based recommendations.[10] Fostering interdisciplinary collaborations and expanding research on HDP disparities can pave the way for inclusive healthcare policies that prioritize maternal and neonatal health. By addressing socioecological determinants and systemic challenges, global maternal healthcare systems can achieve equitable outcomes for all affected populations.

6. Innovations in Healthcare Delivery

Addressing the multifaceted challenges posed by hypertensive disorders of pregnancy (HDPs) requires sustained investment in research, innovations, and policy reforms. While considerable advancements have been made, several gaps remain in understanding the pathophysiology, optimizing therapeutic interventions, and addressing healthcare disparities associated with HDPs. Emerging evidence underscores the need for a deeper exploration of the molecular mechanisms underlying HDPs. Studies focusing on angiogenic factors such as placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 offer promising insights into early detection and disease progression.[9] Investigating novel therapeutic agents targeting these pathways could significantly enhance maternal outcomes. Longitudinal studies examining the intergenerational impacts of HDPs are critical for understanding their long-term effects on offspring health. Expanding genome-wide association studies (GWAS) to diverse populations would uncover genetic susceptibilities, enabling personalized approaches to prevention and treatment.[9] Additionally, clinical trials evaluating the efficacy and safety of antihypertensive agents, including nifedipine and labetalol, across different populations are essential for standardizing treatment protocols.[45] By integrating emerging insights into gut microbiota, epigenetic modifications, and their interplay with traditional pathophysiological mechanisms, we underscore the potential for personalized, microbiome-based, and epigenetic-targeted interventions. Such targeted approaches could transform the clinical landscape of HDP management, enabling precision medicine to address the unique biological and environmental contexts of individual patients. The convergence of maternal nutrition, microbiota manipulation, and epigenetic therapies offers a visionary avenue to mitigate not only immediate pregnancy risks but also long-term intergenerational health consequences. Future research must adopt a systems biology framework, combining multi-omics technologies, artificial intelligence, and longitudinal cohort studies to unravel the intricate networks that govern HDPs. This integrated approach can identify early biomarkers, optimize intervention timing, and ultimately redefine maternal health paradigms. In doing so, we take a step closer to realizing the broader goal: securing safer pregnancies and healthier futures for both mother and child. Policymakers must prioritize equitable access to maternal healthcare services to reduce HDP-related disparities. Expanding antenatal screening programs and integrating HDP risk profiling into community-based healthcare systems can significantly improve early detection rates.[2] Tailored public health campaigns addressing socioecological determinants such as poverty, education, and health literacy are crucial for reducing the prevalence of HDPs in underserved populations. Promoting collaboration between global health organizations and local governments can facilitate the development of culturally relevant healthcare guidelines. Harmonizing international recommendations on aspirin prophylaxis, antihypertensive thresholds, and postpartum monitoring will ensure consistency in clinical practices, ultimately improving maternal and neonatal health outcomes.[10] The adoption of telemedicine platforms for postpartum hypertension management demonstrates the potential for scalable, cost-effective solutions in maternal healthcare.[11] Governments and healthcare institutions should invest in technologies that enable remote blood pressure monitoring, particularly in low-resource settings where access to care is limited. Establishing centralized registries for HDPs could support large-scale epidemiological studies and foster collaboration among researchers. These registries would provide valuable data on prevalence, risk factors, and long-term outcomes, guiding evidence-based policymaking and resource allocation. Healthcare professionals must receive ongoing training on HDP management, emphasizing risk stratification, early intervention, and individualized care strategies. Community-level initiatives, such as workshops and seminars, can empower women with the knowledge needed to recognize HDP symptoms and seek timely medical attention.

The persistent burden of hypertensive disorders in pregnancy (HDPs) underscores the critical need for advancing research to address remaining gaps. Future investigations should prioritize the molecular mechanisms driving HDPs, such as the role of angiogenic factors like placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 in disease onset and progression. Expanding genome-wide association studies (GWAS) across diverse populations

is essential for uncovering genetic predispositions and facilitating the development of personalized care strategies. Emerging evidence highlights the interplay between gut microbiota, epigenetic modifications, and HDP pathophysiology. Research integrating multi-omics approaches could unravel these complex interactions, paving the way for innovative microbiome-based and epigenetic-targeted interventions. Furthermore, understanding the long-term intergenerational impacts of HDPs on offspring health, including their predisposition to cardiovascular and metabolic disorders, remains a crucial area for longitudinal studies. Interdisciplinary collaborations leveraging artificial intelligence and advanced predictive models hold promise for improving risk stratification and early diagnosis of HDPs. Additionally, addressing healthcare disparities, particularly in low-resource settings, must remain a research priority to ensure equitable maternal health outcomes. By focusing on these areas, future research can inspire transformative approaches to HDP prevention and management, ultimately improving health outcomes for mothers and their children.

7. Conclusion

Hypertensive disorders of pregnancy (HDPs) are a critical global challenge to maternal and neonatal health, requiring urgent efforts to reduce their prevalence and complications. This review examines the epidemiology, risk factors, management strategies, and long-term effects of HDPs, emphasizing evidence-based care and early detection of subtypes like gestational hypertension and preeclampsia to prevent severe outcomes such as HELLP syndrome and eclampsia. Innovations like telemedicine and genetic research show promise in managing HDPs, but systemic disparities demand robust public health policies, improved healthcare accessibility, and community education. The intergenerational impact of HDPs underscores the importance of life-course approaches and health monitoring for mothers and children. Personalized nutrition, including probiotics, prebiotics, and micronutrients, may help reduce pregnancy-induced hypertension. Addressing research gaps and disparities requires interdisciplinary collaboration, stronger healthcare systems, and policy initiatives to improve maternal care and outcomes.

Funding

This research did not receive any financial support from funding agencies.

Conflict of interest

The authors declare that they have no conflict of interest.

References

[1] Magee LA, Sharma S, Nathan HL, et al. The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. *PLoS Med* 2019; 16: e1002783.

[2] Alur A, Phipps JE, Simmons LA. Socioecological factors influencing the risk of developing hypertensive disorders of pregnancy in India: a rapid review. *BMC Pregnancy Childbirth* 2024; 24: 669.

[3] Nath A, Sheeba B, Sisira R, et al. Prevalence of hypertension in pregnancy and its associated factors among women attending antenatal clinics in Bengaluru. *J Family Med Prim Care* 2021; 10: 1621–1627.

[4] Das S, Maharjan R, Bajracharya R, et al. Pregnancy outcomes in women with gestational hypertension and preeclampsia at Paropakar Maternity and Women's Hospital, Nepal: A retrospective study. *PLoS One* 2023; 18: e0286287.

[5] *WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia*. Geneva: World Health Organization, http://www.ncbi.nlm.nih.gov/books/NBK140561/ (2011, accessed 31 March 2025).

[6] Bajpai D, Popa C, Verma P, et al. Evaluation and Management of Hypertensive Disorders of Pregnancy. *Kidney360* 2023; 4: 1512–1525.

[7] Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. *Hypertens Res* 2017; 40: 213–220.

[8] Honigberg MC, Zekavat SM, Aragam K, et al. Long-Term Cardiovascular Risk in Women with Hypertension during Pregnancy. *J Am Coll Cardiol* 2019; 74: 2743–2754.

[9] Rayes B, Ardissino M, Slob EAW, et al. Association of Hypertensive Disorders of Pregnancy With Future Cardiovascular Disease. *JAMA Netw Open* 2023; 6: e230034.

[10] Sinkey RG, Battarbee AN, Bello NA, et al. Prevention, Diagnosis and Management of Hypertensive Disorders of Pregnancy: A Comparison of International Guidelines. *Curr Hypertens Rep* 2020; 22: 66.

[11] Hauspurg A, Lemon LS, Quinn BA, et al. A Postpartum Remote Hypertension Monitoring Protocol Implemented at the Hospital Level. *Obstet Gynecol* 2019; 134: 685–691.

[12] Gogoi J, Ahmed SJ, Neog P. Prevalence and associated risk factors of hypertension among pregnant women in rural areas of Dibrugarh District, Assam. *J Family Med Prim Care* 2024; 13: 2709–2718.

[13] Malek AM, Hunt KJ, Turan TN, et al. Hypertensive Disorders of Pregnancy with and without Pre-Pregnancy Hypertension are Associated with Incident Maternal Kidney Disease Subsequent to Delivery. *Hypertension* 2022; 79: 844–854.

[14] Padhan SC, Pradhan P, Panda B, et al. Risk Factors of Pre-eclampsia: A Hospital-Based Case-Control Study. *Cureus* 2023; 15: e42543.

[15] Wu X, Li Q, Lin D, et al. Gut microbiota and hypertensive disorders in pregnancy: evidence from the Mendelian randomization study. *Aging (Albany NY)* 2023; 15: 9105–9127.

[16] Yu J, Zhang B, Miao T, et al. Dietary Nutrition and Gut Microbiota Composition in Patients With Hypertensive Disorders of Pregnancy. *Front Nutr* 2022; 9: 862892.

[17] Deng F, Lei J, Qiu J, et al. DNA methylation landscape in pregnancy-induced hypertension: progress and challenges. *Reprod Biol Endocrinol* 2024; 22: 77.

[18] Kazmi N, Sharp GC, Reese SE, et al. Hypertensive Disorders of Pregnancy and DNA Methylation in Newborns. *Hypertension* 2019; 74: 375–383.

[19] Nankali A, Malek-khosravi Sh, Zangeneh M, et al. Maternal Complications Associated with Severe Preeclampsia. *J Obstet Gynaecol India* 2013; 63: 112–115.

[20] Babore GO, Aregago TG, Ermolo TL, et al. Determinants of pregnancy-induced hypertension on maternal and foetal outcomes in Hossana town administration, Hadiya zone, Southern Ethiopia: Unmatched case-control study. *PLoS One* 2021; 16: e0250548.

[21] Khan S, Chughani G, Amir F, et al. Frequency of Abruptio Placenta in Women With Pregnancy-Induced Hypertension. *Cureus*; 14: e21524.

[22] Akaishi T, Tarasawa K, Hamada H, et al. Prenatal hypertension as the risk of eclampsia, HELLP syndrome, and critical obstetric hemorrhage. *Hypertens Res* 2024; 47: 455–466.

[23] Malmström O, Morken N-H. HELLP syndrome, risk factors in first and second pregnancy: a population-based cohort study. *Acta Obstet Gynecol Scand* 2018; 97: 709–716.

[24] Joseph KS, Lisonkova S, Boutin A, et al. Maternal mortality in the United States: are the high and rising rates due to changes in obstetrical factors, maternal medical conditions, or maternal mortality surveillance? *Am J Obstet Gynecol* 2024; 230: 440.e1-440.e13.

[25] Nair M, Kurinczuk J, Brocklehurst P, et al. Factors associated with maternal death from direct pregnancy complications: a UK national case–control study. *BJOG* 2015; 122: 653–662.

[26] Baumfeld Y, Herskovitz R, Niv ZB, et al. Placenta associated pregnancy complications in pregnancies complicated with placenta previa. *Taiwan J Obstet Gynecol* 2017; 56: 331–335.

[27] Warad C, Midha B, Pandey U, et al. Ocular Manifestations in Pregnancy-Induced Hypertension at a Tertiary Level Hospital in Karnataka, India. *Cureus*; 15: e34887.

[28] Thakur A, Dangal G. Fetomaternal Outcome in Women with Pregnancy Induced Hypertension versus Normotensive Pregnancy. *J Nepal Health Res Counc* 2020; 17: 495–500.

[29] Berhe AK, Ilesanmi AO, Aimakhu CO, et al. Effect of pregnancy induced hypertension on adverse perinatal outcomes in Tigray regional state, Ethiopia: a prospective cohort study. *BMC Pregnancy Childbirth* 2019; 20: 7.

[30] Butali A, Ezeaka C, Ekhaguere O, et al. Characteristics and risk factors of preterm births in a tertiary center in Lagos, Nigeria. *Pan Afr Med J* 2016; 24: 1.

[31] Kim H-R, Lee BK. Outcomes of singleton preterm very low birth weight infants born to mothers with pregnancy-induced hypertension. *Sci Rep* 2023; 13: 6100.

[32] Zhang B, Chen X, Yang C, et al. Effects of hypertensive disorders of pregnancy on the complications in very low birth weight neonates. *Hypertens Pregnancy* 2024; 43: 2314576.

[33] Cohen Y, Gutvirtz G, Avnon T, et al. Chronic Hypertension in Pregnancy and Placenta-Mediated Complications Regardless of Preeclampsia. *J Clin Med* 2024; 13: 1111.

[34] Mehare T, Kebede D. Fetoplacental Weight Relationship in Normal Pregnancy and Pregnancy Complicated by Pregnancy-Induced Hypertension and Abruption of Placenta among Mothers Who Gave Birth in Southern Ethiopia, 2018. *Obstet Gynecol Int* 2020; 2020: 6839416.

[35] Rocha de Moura MD, Margotto PR, Nascimento Costa K, et al. Hypertension induced by pregnancy and neonatal outcome: Results from a retrospective cohort study in preterm under 34 weeks. *PLoS One* 2021; 16: e0255783.

[36] Park Y, Cho GJ, Roh S, et al. Increased Cardiac Arrhythmia After Pregnancy- Induced Hypertension: A South Korean Nationwide Database Study. *J Am Heart Assoc* 2022; 11: e023013.

[37] Huang C, Wei K, Lee PMY, et al. Maternal hypertensive disorder of pregnancy and mortality in offspring from birth to young adulthood: national population based cohort study. *BMJ* 2022; 379: e072157.

[38] Chen J, Guo L, Li S, et al. Efficacy and safety of postural intervention on prevention of deep venous thrombosis of lower extremity in postpartum women with pregnancy-induced hypertension. *Medicine (Baltimore)* 2021; 100: e24959.

[39] Sweeney LC, Lundsberg LS, Culhane JF, et al. Co-existing chronic hypertension and hypertensive disorders of pregnancy and associated adverse pregnancy outcomes. *J Matern Fetal Neonatal Med* 2024; 37: 2305675.

[40] Cameron NA, Everitt IK, Lee KA, et al. Chronic Hypertension in Pregnancy: A Lens Into Cardiovascular Disease Risk and Prevention. *Hypertension* 2023; 80: 1162–1170.

[41] American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. *Obstet Gynecol* 2019; 133: e26–e50.

[42] Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol* 2020; 135: e237–e260.

[43] Vaughn CJ. Drugs and Lactation Database: LactMed. *Journal of Electronic Resources in Medical Libraries* 2012; 9: 272–277.

[44] Park K, Merz CNB, Bello NA, et al. Cardio-Obstetrics Part 3: Acquired Cardiovascular Disorders: JACC Focus Seminar. *J Am Coll Cardiol* 2021; 77: 1799–1812.

[45] Webster LM, Myers JE, Nelson-Piercy C, et al. Labetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy: A Randomized Controlled Trial. *Hypertension* 2017; 70: 915–922.

[46] Webster LM, Conti- Ramsden F, Seed PT, et al. Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta- Analysis. *J Am Heart Assoc* 2017; 6: e005526.

[47] Broekhuijsen K, Ravelli ACJ, Langenveld J, et al. Maternal and neonatal outcomes of pregnancy in women with chronic hypertension: a retrospective analysis of a national register. *Acta Obstet Gynecol Scand* 2015; 94: 1337–1345.

[48] American College of Obstetricians and Gynecologists (ACOG). Hypertensive Pregnancy Disorders: Guidelines and Protocol, https://www.preeclampsia.org/frontend/assets/img/advocacy_resource/Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf (2018, accessed 3 April 2025).

[49] World Health Organization. Operation guidance: Hypertensive Pregnancy Disorder Management Protocol, https://platform.who.int/docs/default-source/mca-documents/policy-documents/operational-guidance/BRN-MN-32-02-OPERATIONALGUIDANCE-2012-eng-Hyptensive-Pregnancy-Disorder-Management-Protocol.pdf (2012, accessed 3 April 2025).

[50] National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management, https://www.nice.org.uk/guidance/ng133?UID=266360187202532504251 (2019, accessed 3 April 2025).

[51] Männistö T, Mendola P, Vääräsmäki M, et al. Elevated Blood Pressure in Pregnancy and Subsequent Chronic Disease Risk. *Circulation* 2013; 127: 681–690.

[52] Garovic VD, White W, Vaughan L, et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. *J Am Coll Cardiol* 2020; 75: 2323–2334.

[53] Malek AM, Wilson DA, Turan TN, et al. Maternal Coronary Heart Disease, Stroke, and Mortality Within 1, 3, and 5 Years of Delivery Among Women With Hypertensive Disorders of Pregnancy and Pre- Pregnancy Hypertension. *J Am Heart Assoc* 2021; 10: e018155.

[54] Guida JP, Costa ML, Parpinelli MA, et al. The impact of hypertension, hemorrhage, and other maternal morbidities on functioning in the postpartum period as assessed by the WHODAS 2.0 36- item tool. *Int J Gynaecol Obstet* 2018; 141: 55–60.

[55] Zhong X, Zhang P. Analysis of risk factors associated with different degrees of postpartum hemorrhage in patients with pregnancy-induced hypertension and construction of a prediction model using line graph. *J Matern Fetal Neonatal Med* 2023; 36: 2239983.

[56] Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. *Am J Obstet Gynecol* 2022; 226: S1211–S1221.

[57] Muti M, Tshimanga M, Notion GT, et al. Prevalence of pregnancy induced hypertension and pregnancy outcomes among women seeking maternity services in Harare, Zimbabwe. *BMC Cardiovasc Disord* 2015; 15: 111.